These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19266466)

  • 21. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration.
    Emerson GG; Flaxel CJ; Lauer AK; Stout JT; Emerson MV; Nolte S; Wilson DJ; Klein ML
    Retina; 2007; 27(6):724-9. PubMed ID: 17621181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA; Hassan TS; Williams GA
    Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The assessment of treatment efficacy in age related macular degeneration by evaluating the oxidative stress markers and OCT measurements.
    Dănulescu R; Costin D
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):328-33. PubMed ID: 24340512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Age-related macular degeneration: therapeutic hopes].
    Behar-Cohen F; Sennlaub F; Berdugo M
    Med Sci (Paris); 2007 Feb; 23(2):127-9. PubMed ID: 17291419
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Age-related macular degeneration--new possibilities for prophylactic measures].
    Frennesson C; Nilsson SE
    Lakartidningen; 2002 Aug; 99(32-33):3194-7. PubMed ID: 12219472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D
    Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
    Abdelfattah NS; Zhang H; Boyer DS; Rosenfeld PJ; Feuer WJ; Gregori G; Sadda SR
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1839-46. PubMed ID: 27082298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-related macular degeneration: clinical findings, histopathology and imaging techniques.
    Zarbin MA; Casaroli-Marano RP; Rosenfeld PJ
    Dev Ophthalmol; 2014; 53():1-32. PubMed ID: 24732758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is there a drug therapy for age-related macular degeneration?--current status and new therapeutic approaches].
    Augustin AJ; Offermann I
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):555-63. PubMed ID: 18516776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New drugs; pegaptanib and ranibizumab].
    van Bronswijk H; Dubois EA; van Meurs JC; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):82-4. PubMed ID: 18265796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.
    Kuehlewein L; Bansal M; Lenis TL; Iafe NA; Sadda SR; Bonini Filho MA; De Carlo TE; Waheed NK; Duker JS; Sarraf D
    Am J Ophthalmol; 2015 Oct; 160(4):739-48.e2. PubMed ID: 26164826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
    Ehlers JP; Spirn MJ; Shah CP; Fenton GL; Baker PS; Regillo CD; Ho AC
    Ophthalmic Surg Lasers Imaging; 2010; 41(2):182-9. PubMed ID: 20307035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Age related macular degeneration].
    Sayen A; Hubert I; Berrod JP
    Rev Prat; 2011 Feb; 61(2):159-64. PubMed ID: 21618758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study.
    Ho L; van Leeuwen R; Witteman JC; van Duijn CM; Uitterlinden AG; Hofman A; de Jong PT; Vingerling JR; Klaver CC
    Arch Ophthalmol; 2011 Jun; 129(6):758-66. PubMed ID: 21670343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.